Benzinga | Oct 18, 2021 08:09AM EDT

Equillium Announces Two Abstracts Accepted For Presentation At The Upcoming Virtual 2021 American Society Of Nephrology Annual Meeting

Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that two abstracts were accepted for presentation at the virtual 2021 American Society of Nephrology (ASN) Annual Meeting to be held November 4-7, 2021.

Title: Itolizumab, a novel anti-CD6 antibody, in systemic lupus patients with proteinuria: An Interim subgroup analysis from EQUALISE a Phase 1b study

First Author: Chaim Putterman, M.D., Professor, Rheumatology, Albert Einstein College of Medicine

ePoster Session: PO1203-3. Glomerular Diseases: Treatment and Outcomes

Abstract Publication #: PO1624

The abstract highlights safety and initial decreases in urine protein/creatinine ratio (UPCR) in patients with systemic lupus erythematosus (SLE) treated with itolizumab.

Title: Itolizumab, a novel anti-CD6 therapy, in systemic lupus erythematosus patients: Interim safety results from the Phase 1b EQUALISE dose-escalation study

First Author: Chaim Putterman, M.D., Professor, Rheumatology, Albert Einstein College of Medicine

ePoster Session: PO1203-3. Glomerular Diseases: Treatment and Outcomes

Abstract Publication #: PO1623

The abstract highlights safety, tolerability and pharmacokinetic and pharmacodynamic results demonstrating dose-proportional increases in drug exposure and rapid and dose-dependent decreases in CD4 cell surface expression of CD6 in patients with systemic lupus erythematosus (SLE).

All ePosters will be available for on-demand viewing by registered attendees on the conference platform starting Thursday, November 4, 2021, at 10:00 a.m. PT.